Analytical White Papers
Free analytical and research White Papers on the topic of reimbursement, HTA and evidence requirements for medical devices and IVD tests in Europe
Recent news and posts
The 2024 version of the SwissDRG released
On November 30, 2023, the entity managing the DRG system in Switzerland, SwissDRG, published the final version of the 2024 DRG system. In total, 34 new DRGs were introduced. They concern cardiovascular, endocrine, gastrointestinal, men’s health, nephrology and urology, neurology and neurosurgery, neuromodulation, obstetrics and gynecology, orthopedics, pulmonary, and other technology groups. Some examples of the newly introduced DRGs are:
- F36E Diseases and disorders of the cardiovascular system with complex intensive care > 196/360 resource points;
- B21E Implantation of other electrodes;
- H62C Pancreatic diseases except for malignant neoplasm, more than one day in hospital;
- B61D Paraplegia/tetraplegia or spinal cord trauma with specific or complicating procedure;
- I04C Knee revision or replacement with complicating diagnosis or arthrodesis;
- E70C Whooping cough and acute bronchitis, age > 0 years, more than one day in hospital.
Also, two new add-on reimbursement categories related to in-vitro diagnostics and peripheral vascular field were introduced.
More information can be found here.
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.